Prime Medicine Inc (NASDAQ:PRME)’s traded shares stood at 0.46 million during the last session, with the company’s beta value hitting 2.27. At the close of trading, the stock’s price was $4.42, to imply an increase of 6.76% or $0.28 in intraday trading. The PRME share’s 52-week high remains $13.60, putting it -207.69% down since that peak but still an impressive 9.73% since price per share fell to its 52-week low of $3.99. The company has a valuation of $530.53M, with an average of 0.56 million shares in intraday trading volume over the past 10 days and average of 828.98K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Prime Medicine Inc (PRME), translating to a mean rating of 1.33. Of 5 analyst(s) looking at the stock, 0 analyst(s) give PRME a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.45.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Prime Medicine Inc (NASDAQ:PRME) trade information
After registering a 6.76% upside in the last session, Prime Medicine Inc (PRME) has traded red over the past five days. The 5-day price performance for the stock is 4.25%, and -21.77% over 30 days. With these gigs, the year-to-date price performance is -50.11%. Short interest in Prime Medicine Inc (NASDAQ:PRME) saw shorts transact 14.91 million shares and set a 21.63 days time to cover.
The extremes give us $12 and $23 for target low and target high price respectively. As such, PRME has been trading -420.36% off suggested target high and -171.49% from its likely low.
Prime Medicine Inc (PRME) estimates and forecasts
Looking at statistics comparing Prime Medicine Inc share performance against respective industry, we note that the company has underperformed competitors. Prime Medicine Inc (PRME) shares are -46.88% down over the last 6 months, with its year-to-date growth rate lower than industry average at 13.30% against 18.60%. Revenue is forecast to grow 18.20% this quarter before jumping 37.50% for the next one.
Revenue forecast for the current quarter as set by 10 analysts is 2.33M. Meanwhile, for the current quarter, a total of 9 analyst(s) estimate revenue growth to 620k.
PRME Dividends
Prime Medicine Inc has its next earnings report out on 2024-Aug-08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Prime Medicine Inc insiders hold 26.27% of total outstanding shares, with institutional holders owning 68.03% of the shares at 92.27% float percentage. In total, 68.03% institutions holds shares in the company.
We also have ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF as the top two Mutual Funds with the largest holdings of the Prime Medicine Inc (PRME) shares. Going by data provided on Jul 31, 2024 , ARK ETF Tr-ARK Genomic Revolution ETF holds roughly 2.92 shares. This is just over 2.44% of the total shares, with a market valuation of $12.93 million. Data from the same date shows that the other fund manager holds a little less at 2.66, or 2.22% of the shares, all valued at about 11.75 million.
